Peptide News Digest

#Amaze-12

2 stories

Industry · View digest

Novo Nordisk Amycretin vs CagriSema Strategic Positioning After TRIUMPH-1 — Phase 3 AMAZE-12 vs REDEFINE 11 Read

Industry commentary May 22 framed Novo Nordisk's strategic response to retatrutide's TRIUMPH-1 readout as a two-track amylin strategy. CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) is the near-term play — Phase 3 REDEFINE-1 and REDEFINE-2 complete, FDA filing under review with decision expected late 2026, and Novo positioning the safety profile as the competitive edge after REDEFINE-4 missed non-inferiority versus tirzepatide 15 mg in February 2026. Amycretin (dual GLP-1/amylin agonist) is the long-term bet — AMAZE-12 Phase 3 began recruiting May 18 testing the dual agonist for weight maintenance, with Phase 1 results showing 22% weight loss at 36 weeks weekly subcutaneous and 13.1% at 12 weeks oral. The CagriSema higher-dose Phase 3 starts H2 2026; REDEFINE-11 reads out H1 2027. Combined, the amylin axis is structurally Novo's most direct response to Lilly's triple-agonist mechanism — adding amylin tone (slower gastric emptying, satiety persistence, weight-maintenance) rather than competing on glucagon-driven energy expenditure.

Clinical Trials · View digest

Novo Nordisk AMAZE-12 Phase 3 Amycretin Trial Begins Recruitment May 18 — Dual GLP-1/Amylin Receptor Agonist for Weight Maintenance

Novo Nordisk's AMAZE-12 Phase 3 trial of amycretin — a dual GLP-1 and amylin receptor agonist — began recruiting on May 18, 2026. The trial evaluates amycretin specifically for weight maintenance after initial weight loss, distinguishing it from AMAZE-1 (which measures body weight change over 84 weeks). The amycretin clinical rationale rests on Phase 1 weekly subcutaneous dosing producing 22% weight reduction at 36 weeks and oral formulation producing 13.1% at 12 weeks — both reported in the Lancet earlier in 2026. Amycretin sits within Novo's next-generation pipeline alongside CagriSema (cagrilintide + semaglutide, FDA filing under review with decision expected late 2026) and the orexin-related pipeline acquired via Centessa. The amycretin program is structurally Novo's most direct response to Lilly's retatrutide.